Gene Therapy Advancements for Rare Genetic Disorders: Clinical, Ethical, and Regulatory Challenges

Abstract

This study examines the advancements in gene therapy as a promising therapeutic strategy for rare genetic disorders, focusing on clinical, ethical, and regulatory dimensions. The results highlight the transformative role of gene-editing technologies, particularly CRISPR-Cas9, in enabling precise genomic modifications and fostering the development of therapies for conditions such as spinal muscular atrophy (SMA), adenosine deaminase severe combined immunodeficiency (ADA-SCID), and metachromatic leukodystrophy (MLD). Evidence from clinical trials demonstrates substantial improvements in patient outcomes, with therapies like onasemnogene abeparvovec (Zolgensma) showing enhanced motor function in SMA patients and Strimvelis delivering durable survival benefits in ADA-SCID cases. Despite these successes, the analysis reveals ongoing challenges related to safety concerns, vector delivery efficiency, high costs, and long-term monitoring requirements. Ethical considerations, including equitable access and potential off-target effects, remain central to the discourse, while regulatory frameworks struggle to balance rapid innovation with patient safety. Overall, the findings underscore the dual reality of gene therapy: it is both a revolutionary medical breakthrough and a field requiring robust clinical oversight, interdisciplinary collaboration, and ethical governance to ensure sustainable integration into healthcare systems.